default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

SCM Life Science, MitoImmune Therapeutics to develop new treatment

Lee Han-soo  Published 2019.07.11  16:40  Updated 2019.07.11 16:57

공유
default_news_ad2

SCM Life Science said that it has agreed with MitoImmune Therapeutics to develop a new treatment, which combines clonal mesenchymal stem cells (cMSC) and mitochondria technology.

SCM Life Science CEO Rhee Byung-gun (left) and MitoImmune Therapeutics CEO Kim Soon-ha signed a business partnership contract at the former's headquarters in Incheon, on Thursday.

The two companies will carry out the agreement soon to start research into therapeutic agents for intractable, inflammatory, and rare diseases.

"We hope to develop a drug for rare intractable diseases that can enter the global market by combing MitoImmune Therapeutics' mitochondrial control technology and our cMSC technology," SCM Life Science CEO Rhee Byung-gun said.

MitoImmune Therapeutics CEO Kim Soon-ha also said, "Our company expects that its mitochondria platform will provide a differentiated solution for the treatment of rare intractable diseases by modulating mitochondrial functions for SCM Life Science's cMSC."

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch